Indications
Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. For hepatitis C virus (HCV) genotype specific activity.
Composition
- Active substance
- simeprevir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Olysio
- Active substance
- simeprevir
- ATC code
- J05AE14
- Therapeutic area
- Hepatitis C, Chronic
- Marketing authorisation holder
- Janssen-Cilag International NV
- Status
- Withdrawn
- EU authorisation